Vyome Therapeutics Inc.

Former executives from the autologous chimeric antigen receptor T-cell (CAR-T) therapy developer Juno Therapeutics Inc. , following the company's $9bn acquisition by Celgene Corp. last year, have l

Ambrx raises $45m in late-stage financing round Ambrx Inc. (protein therapeutics known as bio-conjugates) raised $45m in a late-stage financing round led by Apricot Capital and Northeast Securitie

Not every private biopharmaceutical firm can be Moderna Therapeutics LLC , bringing in hundreds of millions of venture capital dollars in a single fundraising attempt, but startups in the hot immun

NEW DELHI - Vyome Biosciences Pvt. Ltd. , one of a new clutch of Indian start-up pharmaceutical companies doing pioneering research, says it has notched up an important milestone for its flagship i